Phaseline

Companies › TeneoSeven

TeneoSeven: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Jun 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NTB-928–Phase 1Relapsed/Refractory Ovarian CarcinomaJun 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07690189NTB-928Phase 1Relapsed/Refractory Ovarian CarcinomaOncologyJun 2028

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.